Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 383,200 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 383,200 shares of the company’s stock in a transaction on Monday, December 22nd. The shares were sold at an average price of $21.74, for a total transaction of $8,330,768.00. Following the sale, the director directly owned 2,031,181 shares in the company, valued at $44,157,874.94. This trade represents a 15.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Immunome Stock Performance

Shares of IMNM stock traded down $0.30 during mid-day trading on Tuesday, hitting $21.73. The company’s stock had a trading volume of 4,020,725 shares, compared to its average volume of 1,283,040. The company has a market cap of $1.99 billion, a PE ratio of -7.37 and a beta of 2.17. The company’s fifty day simple moving average is $17.84 and its 200-day simple moving average is $12.82. Immunome, Inc. has a 52 week low of $5.15 and a 52 week high of $25.30.

Immunome (NASDAQ:IMNM) last announced its earnings results on Thursday, November 6th. The company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.08). Immunome had a negative net margin of 1,687.08% and a negative return on equity of 76.50%. On average, equities analysts anticipate that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Guggenheim lifted their price objective on shares of Immunome from $25.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Wall Street Zen upgraded shares of Immunome from a “sell” rating to a “hold” rating in a report on Saturday, November 22nd. The Goldman Sachs Group started coverage on shares of Immunome in a report on Monday, September 22nd. They set a “buy” rating and a $26.00 price objective on the stock. Craig Hallum initiated coverage on shares of Immunome in a research report on Friday, September 5th. They set a “buy” rating and a $26.00 price objective on the stock. Finally, Truist Financial started coverage on Immunome in a research report on Monday, December 1st. They issued a “buy” rating and a $36.00 target price for the company. Ten research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Immunome presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.09.

Institutional Trading of Immunome

Several institutional investors and hedge funds have recently modified their holdings of the stock. Assetmark Inc. bought a new position in shares of Immunome in the third quarter valued at approximately $39,000. BNP Paribas Financial Markets grew its holdings in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after buying an additional 2,909 shares in the last quarter. Tower Research Capital LLC TRC raised its position in Immunome by 121.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock valued at $65,000 after buying an additional 3,802 shares during the last quarter. BIT Capital GmbH bought a new position in Immunome during the 3rd quarter valued at $69,000. Finally, Russell Investments Group Ltd. purchased a new position in Immunome during the 3rd quarter worth $76,000. 44.58% of the stock is owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.